ELOX
Eloxx Pharmaceuticals, Inc.
$13.52
+6.96%
No data for this timeframe.
Vol
SEC Reports5
Exchange OTC·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001035354·Prev Close $12.64
Recent Activity
Jun 10, 2026
Insider
Aggarwal Sumit was granted 328,833 shares
President and CEO
Jun 9, 2026
SEC
Eloxx Pharmaceuticals' S-1 registration statement (File No. 333-295651) became effective on June 8, 2026, clearing the w
EFFECT — Impact 5/10
Jun 8, 2026
Insider
Walts Alan Edmund was granted 8,590 shares
Director
Jun 8, 2026
Insider
Rubin Steven D was granted 4,018 shares
Director
Jun 4, 2026
SEC
Eloxx Pharmaceuticals filed Amendment No. 2 to its S-1 registration statement for a public offering of 2,730,000 shares
S-1/A — Impact 5/10
Jun 1, 2026
SEC
Eloxx Pharmaceuticals filed an amended S-1 registration statement to offer 1.5 million shares of common stock and pre-fu
S-1/A — Impact 5/10
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 11, 2023 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Apr 6, 2023 | Oppenheimer | REITERATE | Outperform |
Latest Reports
NEUTRAL
EFFECT
5/10
Eloxx Pharmaceuticals' S-1 registration statement (File No. 333-295651) became effective on June 8, 2026, clearing the w
Jun 9, 2026
NEUTRAL
S-1/A
5/10
Eloxx Pharmaceuticals filed Amendment No. 2 to its S-1 registration statement for a public offering of 2,730,000 shares
Jun 4, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Aggarwal Sumit | A | $0.00 |
| Jun 8, 2026 | Walts Alan | A | $0.00 |
| Jun 8, 2026 | Rubin Steven | A | $0.00 |
| Jun 8, 2026 | Kjellson Nina | A | $0.00 |
| Jun 8, 2026 | Webster Stephen | A | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
7 unique insiders with 22 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Aggarwal Sumit | President and CEO | AWARD | 328,833 | — | — |
| Jun 8, 2026 | Walts Alan Edmund | Director | AWARD | 8,590 | — | — |
| Jun 8, 2026 | Rubin Steven D | Director | AWARD | 4,018 | — | — |
| Jun 8, 2026 | Kjellson Nina S | Director | AWARD | 13,587 | — | — |
| Jun 8, 2026 | Webster Stephen W | Director | AWARD | 13,587 | — | — |
| May 27, 2026 | Coastlands Capital LP | 10%+ Owner | J | 1,250,000 | — | — |
| May 27, 2026 | Coastlands Capital LP | 10%+ Owner | J | 1,250,000 | — | — |
| May 27, 2026 | Domicilium Real Estate Fund III LP | 10%+ Owner | J | 113,636 | — | — |
| May 27, 2026 | Domicilium Real Estate Fund III LP | 10%+ Owner | J | 113,636 | — | — |
| Feb 28, 2026 | Aggarwal Sumit | President and CEO | EXERCISE | 260,946 | $0.1500 | $39.1K |
| Jan 24, 2026 | Rubin Steven D | Director | EXERCISE | 1,875 | — | — |
| Jan 24, 2026 | Aggarwal Sumit | President and CEO | EXERCISE | 15,000 | — | — |
| Jan 24, 2026 | Walts Alan Edmund | Director | EXERCISE | 1,875 | — | — |
| Sep 19, 2025 | Walts Alan Edmund | Director | AWARD | 395,680 | — | — |
| Sep 19, 2025 | Aggarwal Sumit | President and CEO | AWARD | 3,597,090 | — | — |
| Sep 19, 2025 | Aggarwal Sumit | President and CEO | AWARD | 1,000,000 | — | — |
| Sep 19, 2025 | Rubin Steven D | Director | AWARD | 179,854 | — | — |
| Aug 14, 2025 | Aggarwal Sumit | President and CEO | EXERCISE | 60,390 | — | — |
| Aug 14, 2025 | Aggarwal Sumit | President and CEO | EXERCISE | 196,880 | $0.000100 | $19.69 |
| Oct 16, 2024 | Aggarwal Sumit | President and CEO | D | 42,790 | — | — |
| Oct 16, 2024 | Aggarwal Sumit | President and CEO | AWARD | 42,790 | — | — |
| Feb 6, 2022 | Aggarwal Sumit | President and CEO | AWARD | 42,790 | — | — |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 4.8/10.
NEUTRAL
EFFECT
5/10
Eloxx Pharmaceuticals' S-1 registration statement (File No. 333-295651) became effective on June 8,
Jun 9, 2026
NEUTRAL
S-1/A
5/10
Eloxx Pharmaceuticals filed Amendment No. 2 to its S-1 registration statement for a public offering
Jun 4, 2026
NEUTRAL
S-1/A
5/10
Eloxx Pharmaceuticals filed an amended S-1 registration statement to offer 1.5 million shares of com
Jun 1, 2026
NEUTRAL
8-K
4/10
Eloxx Pharmaceuticals filed an 8-K detailing a 1-for-11 reverse stock split and authorized share red
Jun 1, 2026
NEUTRAL
S-1
5/10
Eloxx Pharmaceuticals filed an S-1 registration statement for a proposed public offering of common s
May 7, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jul 2023): 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2024-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2023-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jul 11, 2023 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Apr 6, 2023 | Oppenheimer | REITERATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2024 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Aug 1, 2024 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jul 1, 2024 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jun 1, 2024 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.